Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind, placebo-controlled, multi-center trial evaluating CM313 for immune thrombocytopenia; currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• CM313

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Immune Thrombocytopenia, Treatment | Phase 2 | Status: ACTIVE_NOT_RECRUITING